DrugPatentWatch Database Preview
Details for Patent: 7,635,704
Which drugs does patent 7,635,704 protect, and when does it expire?
Patent 7,635,704 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.
This patent has thirty-five patent family members in twenty-six countries.
Summary for Patent: 7,635,704
| Title: | Stable crystal of 4-oxoquinoline compound |
| Abstract: | Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractmetry. |
| Inventor(s): | Satoh; Motohide (Osaka, JP), Motomura; Takahisa (Osaka, JP), Matsuda; Takashi (Osaka, JP), Kondo; Kentaro (Osaka, JP), Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP) |
| Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
| Application Number: | 11/133,471 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,635,704 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Use; |
Drugs Protected by US Patent 7,635,704
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | TREATMENT OF HIV INFECTION | Start Trial | ||
| Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | TREATMENT OF HIV INFECTION | Start Trial | ||
| Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-001 | Sep 24, 2014 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | TREATMENT OF HIV INFECTION | Start Trial | ||
| Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-002 | Sep 24, 2014 | DISCN | Yes | No | Start Trial | Start Trial | Y | Y | TREATMENT OF HIV INFECTION | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,635,704
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2004-150979 | May 20, 2004 |
International Family Members for US Patent 7,635,704
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 049280 | Start Trial | |||
| Argentina | 096100 | Start Trial | |||
| Australia | 2005245296 | Start Trial | |||
| Brazil | PI0510114 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
